Vivien N. Jacobs

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu et al. · Cancer Discovery · 2014 · 2.2K citations · Full text

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Tim P. Green, Mike Fennell, Robin Whittaker et al. · Molecular Oncology · 2009 · 254 citations · Full text

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo

Catherine A. Eberlein, Jane Kendrew, Karen McDaid et al. · Oncogene · 2012 · 86 citations

αVβ6 Integrin, Tumour Growth, Medicine +9

AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i>

Sarah A. Loddick, Sarah J. Ross, Andrew Thomason et al. · Molecular Cancer Therapeutics · 2013 · 77 citations · Full text

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Barry R. Davies, Nin Guan, Armelle Logié et al. · Molecular Cancer Therapeutics · 2015 · 70 citations